First Test That Predicts Severe Outcomes In COVID-19 Patients Receives CE Mark
MeMed’s test measures immune system response to assess a patient’s COVID-19 trajectory.
You may also be interested in...
The company will use the money to fund its US commercialization strategy and continue to develop its host response-based product pipeline.
Kfir Oved, co-founder and CTO of MeMed, talked to Medtech Insight about diagnostic testing that can differentiate bacterial and viral infections to fight antimicrobial resistance.
Sensyne obtained UK regulatory approval for its SYNE-COV machine learning algorithm to assess the long-term risks of COVID-19.